Hidradenitis Suppurativa Foundation Inc
721 Chestnut St
Manchester, NH 03104
- This organization is a 501(c)(3) Public Charity.
- This organization is required to file an IRS Form 990-N.
- Financial information in this report is derived from the organization’s December 31, 2006 Form 990.
Chief Executive Profile
Dr. Danby is a dermatologist with an interest in the acnes, a group of diseases that includes common acne, acne rosacea, and the most serious variant, acne inversa (also known as hidradenitis suppurativa). Hi research has focused on the cause of the disorder (a defect in the support of the wall of the folliculosebaceous structure), the trigger of the disease (hormones snd growth factors), the use of diet in prevention of the disease and the use of early and limited surgical management through unroofing to stop the disease process as early as possible while getting the hormonal and dietary influences under control.
MISSION AND PROGRAMS
The Hidradenitis Suppurativa Foundation, Inc. (HSF) is a 501(c)(3) nonprofit public benefit corporation dedicated to improving the quality of life and quality of care for individuals and families affected by Hidradenitis Suppurativa (HS). The HSF fosters and encourages worldwide research by developing and supporting an interdisciplinary family of scientists and physicians devoted to studying the molecular and cellular basis of HS, in order to develop and deliver more effective forms of treatment and preventative measures for those with this common, debilitating, and eminently chronic disease.
|Program:||Global Educational Program|
|Population Served:||Disabled, General or Disability Unspecified|
1.Support and sustain an international and interdisciplinary family of scientists and physicians devoted to HS research and to developing more effective forms of diagnosis, therapy and prevention. Maintain a comprehensive and educational website for researchers, doctors, patients, and the friends and families of affected patients. 2. Maintain a professionally organized virtual HS library/scientific database. 3. Maintain a Physician Action Network to assist doctors, patients and their families find doctors experienced in treating HS. 4. Host International HSF Symposia to forge new and productive international research. 5. Offer grants and fellowships to encourage the best and the brightest? to devote their energies and creativity to HS research. 6. Provide International HS Research Awards to recognize new investigators and others for their outstanding achievements in Hidradenitis Suppurativa research. 7. Support the development of a global HS Patient Registry. 8. Encourage and support the establishment of global Clinical Centers of Excellence for HS. 9. Actively raise the profile and understanding of HS through global media, educational campaigns, governments and industry.
|Program:||Stem Cell Research|
|Population Served:||General Public/Unspecified|
Examination of tissue from active lesions, particularly the invasive proliferative gelatinous mass (IPGM) to discover and delineated the role, if any, of stem cells in the formation of this material.
Revenue and Expenses Fiscal Year
Balance Sheet Fiscal Year Ending December 31, 2006
Note: The balance sheet gives a snapshot of the financial health of an organization at a particular point in time. An organization’s total assets should generally exceed its total liabilities, or it cannot survive long, but the types of assets and liabilities also must be considered. For instance, an organization’s current assets (cash, receivables, securities, etc.) should be sufficient to cover its current liabilities (payables, deferred revenue, current year loan, and note payments). Otherwise, the organization may face solvency problems. On the other hand, an organization whose cash and equivalents greatly exceed its current liabilities might not be putting its money to best use.
|Assets||January 1, 2006||December 31, 2006||Change|
|Cash & Equivalent||$13,277||$10,551||($2,726)|
|Pledges & Grants Receivable||$0||$0||$0|
|Inventories for Sale or Use||$0||$0||$0|
|Liabilities||January 1, 2006||December 31, 2006||Change|
|Loans and Notes||$0||$0||$0|
|Tax-Exempt Bond Liabilities||$0||$0||$0|